Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

New frontiers in pediatric Allo-SCT

Bone Marrow Transplantation volume 49, pages 1139–1145 (2014)Cite this article

Subjects

Abstract

The inaugural meeting of ‘New Frontiers in Pediatric Allogeneic Stem Cell Transplantation’ organized by the Pediatric Blood and Transplant Consortium (PBMTC) was held at the American Society of Pediatric Hematology and Oncology Annual Meeting. This meeting provided an international platform for physicians and investigators active in the research and utilization of pediatric Allo-SCT in children and adolescents with malignant and non-malignant disease (NMD), to share information and develop future collaborative strategies. The primary objectives of the conference included: (1) to present advances in Allo-SCT in pediatric ALL and novel pre and post-transplant immunotherapy; (2) to highlight new strategies in alternative allogeneic stem cell donor sources for children and adolescents with non-malignant hematological disorders; (3) to discuss timing of immune reconstitution after Allo-SCT and methods of facilitating more rapid recovery of immunity; (4) to identify strategies of utilizing Allo-SCT in pediatric myeloproliferative disorders; (5) to develop diagnostic and therapeutic approaches to hematological complications post pediatric Allo-SCT; (6) to enhance the understanding of new novel cellular therapeutic approaches to pediatric malignant and non-malignant hematological disorders; and (7) to discuss optimizing drug therapy in pediatric recipients of Allo-SCT. This paper will provide a brief overview of the conference.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL et al. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase III COG/PBMTC trial. Blood 2014; 123: 2017–2025.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009; 27: 377–384.

    Article  PubMed  Google Scholar 

  3. Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood 2012; 120: 468–472.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M et al. Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. J Clin Oncol 2009; 27: 5175–5181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Nachman JB, Heerema NA, Sather H, Camitta B, Forestier E, Harrison CJ et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 2007; 110: 1112–1115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hochberg J, Khaled S, Forman SJ, Cairo MS . Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission. Br J Haematol 2013; 161: 27–42.

    Article  CAS  PubMed  Google Scholar 

  7. Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. Biol Blood Marrow Transplant 2012; 18: 979–981.

    Article  PubMed  Google Scholar 

  8. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S . Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003; 32: 543–548.

    Article  CAS  PubMed  Google Scholar 

  9. Davies SM, Ramsay NK, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 340–347.

    Article  CAS  PubMed  Google Scholar 

  10. Eapen M, Raetz E, Zhang MJ, Muehlenbein C, Devidas M, Abshire T et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Blood 2006; 107: 4961–4967.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572–1579.

    CAS  PubMed  Google Scholar 

  12. Bader P, Kreyenberg H, Hoelle W, Dueckers G, Handgretinger R, Lang P et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004; 22: 1696–1705.

    Article  PubMed  Google Scholar 

  13. Barth M, Raetz E, Cairo MS . The future role of monoclonal antibody therapy in childhood acute leukaemias. Br J Haematol 2012; 159: 3–17.

    Article  CAS  PubMed  Google Scholar 

  14. Kreitman RJ, Pastan I . Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011; 17: 6398–6405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120: 5185–5187.

    Article  CAS  PubMed  Google Scholar 

  16. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493–2498.

    Article  CAS  PubMed  Google Scholar 

  17. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509–1518.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Cairo MS, Rocha V, Gluckman E, Hale G, Wagner J . Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors. Biol Blood Marrow Transplant 2008; 14 (1 Suppl 1): 44–53.

    Article  PubMed  Google Scholar 

  19. Horan J, Wang T, Haagenson M, Spellman SR, Dehn J, Eapen M et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood 2012; 120: 2918–2924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011; 118: 5957–5964.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010; 115: 2704–2708.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004; 104: 1201–1203.

    Article  CAS  PubMed  Google Scholar 

  23. Sodani P, Isgro A, Gaziev J, Polchi P, Paciaroni K, Marziali M et al. Purified T-depleted, CD34+ peripheral blood and bone marrow cell transplantation from haploidentical mother to child with thalassemia. Blood 2010; 115: 1296–1302.

    Article  CAS  PubMed  Google Scholar 

  24. Freed J, Talano J, Small T, Ricci A, Cairo MS . Allogeneic cellular and autologous stem cell therapy for sickle cell disease: 'whom, when and how'. Bone Marrow Transplant 2012; 47: 1489–1498.

    Article  CAS  PubMed  Google Scholar 

  25. Wagner JE, Eapen M, MacMillan ML, Harris RE, Pasquini R, Boulad F et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2007; 109: 2256–2262.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Bartelink IH, Belitser SV, Knibbe CA, Danhof M, de Pagter AJ, Egberts TC et al. Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant 2013; 19: 305–313.

    Article  PubMed  Google Scholar 

  27. Renard C, Barlogis V, Mialou V, Galambrun C, Bernoux D, Goutagny MP et al. Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children. Br J Haematol 2011; 152: 322–330.

    Article  PubMed  Google Scholar 

  28. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091–2101.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Srinivasan A, Wang C, Srivastava DK, Burnette K, Shenep JL, Leung W et al. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19: 94–101.

    Article  PubMed  Google Scholar 

  30. Boeckh M, Ljungman P . How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009; 113: 5711–5719.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Engelhard D, Akova M, Boeckh MJ, Freifeld A, Sepkowitz K, Viscoli C et al. Bacterial infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009; 44: 467–470.

    Article  CAS  PubMed  Google Scholar 

  32. Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012; 1: CD004386.

    PubMed  Google Scholar 

  33. Imran H, Tleyjeh IM, Arndt CA, Baddour LM, Erwin PJ, Tsigrelis C et al. Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 2008; 27: 53–63.

    Article  CAS  PubMed  Google Scholar 

  34. Roman E, Osunkwo I, Militano O, Cooney E, van de Ven C, Cairo MS . Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 2008; 50: 325–330.

    Article  PubMed  Google Scholar 

  35. Shereck EB, Cooney E, van de Ven C, Della-Lotta P, Cairo MS . A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Pediatr Blood Cancer 2007; 49: 306–312.

    Article  PubMed  Google Scholar 

  36. Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH et al. Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant 2013; 19: 552–561.

    Article  PubMed  Google Scholar 

  37. Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009; 44: 521–526.

    Article  CAS  PubMed  Google Scholar 

  38. McCune JS, Baker KS, Blough DK, Gamis A, Bemer MJ, Kelton-Rehkopf MC et al. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J Clin Pharmacol 2013; 53: 264–275.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Le Gall JB, Milone MC, Waxman IM, Shaw LM, Harrison L, Duffy D et al. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients. Bone Marrow Transplant 2013; 48: 19–25.

    Article  CAS  PubMed  Google Scholar 

  40. Bartelink IH, Boelens JJ, Bredius RG, Egberts AC, Wang C, Bierings MB et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin Pharmacokinet 2012; 51: 331–345.

    Article  CAS  PubMed  Google Scholar 

  41. Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V et al. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant 2010; 16: 333–343.

    Article  CAS  PubMed  Google Scholar 

  42. Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004; 10: 246–258.

    Article  CAS  PubMed  Google Scholar 

  43. Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011; 29: 2827–2832.

    Article  CAS  PubMed  Google Scholar 

  44. Suttorp M, Yaniv I, Schultz KR . Controversies in the treatment of CML in children and adolescents: TKIs versus BMT? Biol Blood Marrow Transplant 2011; 17 (1 Suppl): S115–S122.

    Article  PubMed  Google Scholar 

  45. Geyer MB, Jacobson JS, Freedman J, George D, Moore V, van de Ven C et al. A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. Br J Haematol 2011; 155: 218–234.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Strahm B, Nollke P, Zecca M, Korthof ET, Bierings M, Furlan I et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia 2011; 25: 455–462.

    Article  CAS  PubMed  Google Scholar 

  47. Sanz J, Arriaga F, Montesinos P, Orti G, Lorenzo I, Cantero S et al. Autoimmune hemolytic anemia following allogeneic hematopoietic stem cell transplantation in adult patients. Bone Marrow Transplant 2007; 39: 555–561.

    Article  CAS  PubMed  Google Scholar 

  48. Horn B, Viele M, Mentzer W, Mogck N, DeSantes K, Cowan M . Autoimmune hemolytic anemia in patients with SCID after T cell-depleted BM and PBSC transplantation. Bone Marrow Transplant 1999; 24: 1009–1013.

    Article  CAS  PubMed  Google Scholar 

  49. Danchaivijitr P, Yared J, Rapoport AP . Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol 2011; 86: 331–332.

    Article  PubMed  Google Scholar 

  50. Rovira J, Cid J, Gutierrez-Garcia G, Pereira A, Fernandez-Aviles F, Rosinol L et al. Fatal immune hemolytic anemia following allogeneic stem cell transplantation: report of 2 cases and review of literature. Transfus Med Rev 2013; 27: 166–170.

    Article  PubMed  Google Scholar 

  51. Laskin BL, Goebel J, Davies SM, Jodele S . Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011; 118: 1452–1462.

    Article  CAS  PubMed  Google Scholar 

  52. Daikeler T, Labopin M, Ruggeri A, Crotta A, Abinun M, Hussein AA et al. New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood 2013; 121: 1059–1064.

    Article  CAS  PubMed  Google Scholar 

  53. Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J et al. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant 2012; 16: E39–E42.

    Article  PubMed  Google Scholar 

  54. Jodele S, Laskin BL, Goebel J, Khoury JC, Pinkard SL, Carey PM et al. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy? Transfusion 2013; 53: 661–667.

    Article  CAS  PubMed  Google Scholar 

  55. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 4693–4699.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID . Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16: 232–236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367: 2305–2315.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Ruggeri L, Mancusi A, Perruccio K, Burchielli E, Martelli MF, Velardi A . Natural killer cell alloreactivity for leukemia therapy. J Immunother 2005; 28: 175–182.

    Article  CAS  PubMed  Google Scholar 

  59. Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, Cooper LJ et al. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res 2013; 19: 2132–2143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Supported by grants from the NCI (#1R13CA177155-01), NHLBI (#5U10HL069254-13), Pediatric Cancer Research Foundation, Children’s Cancer Fund, NMDP Foundation, and St Baldrick’s Foundation.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA,

    J M Talano

  2. Department of Pediatrics, University of Utah, Salt Lake City, UT, USA

    M A Pulsipher

  3. Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, USA

    H J Symons

  4. Department of Pediatrics, New York Medical College, Valhalla, NY, USA,

    O Militano, E Morris & M S Cairo

  5. Oregon Health and Science University, Portland, OR, USA

    E B Shereck

  6. Children’s Hospital Colorado, Aurora, CO, USA

    R H Giller

  7. Pediatric Blood and Marrow Transplant Consortium, Monrovia, CA, USA

    L Hancock

  8. Department of Medicine, New York Medical College, Valhalla, NY, USA,

    M S Cairo

  9. Department of Pathology, New York Medical College, Valhalla, NY, USA,

    M S Cairo

  10. Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA,

    M S Cairo

  11. Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY, USA,

    M S Cairo

Authors
  1. J M Talano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M A Pulsipher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H J Symons
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. O Militano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E B Shereck
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R H Giller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. L Hancock
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M S Cairo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M S Cairo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Talano, J., Pulsipher, M., Symons, H. et al. New frontiers in pediatric Allo-SCT. Bone Marrow Transplant 49, 1139–1145 (2014). https://doi.org/10.1038/bmt.2014.89

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.89

This article is cited by

Search

Advanced search

Quick links